These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 17177577)
1. Irritable bowel syndrome. Spinelli A Clin Drug Investig; 2007; 27(1):15-33. PubMed ID: 17177577 [TBL] [Abstract][Full Text] [Related]
2. The use of anti-spasmodics in the treatment of irritable bowel syndrome: focus on otilonium bromide. Forte E; Pizzoferrato M; Lopetuso L; Scaldaferri F Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):25-37. PubMed ID: 22338545 [TBL] [Abstract][Full Text] [Related]
3. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Clavé P; Acalovschi M; Triantafillidis JK; Uspensky YP; Kalayci C; Shee V; Tack J; Aliment Pharmacol Ther; 2011 Aug; 34(4):432-42. PubMed ID: 21679214 [TBL] [Abstract][Full Text] [Related]
4. IBS and the role of otilonium bromide. Boeckxstaens G; Corazziari ES; Mearin F; Tack J Int J Colorectal Dis; 2013 Mar; 28(3):295-304. PubMed ID: 23178991 [TBL] [Abstract][Full Text] [Related]
6. Role of antispasmodics in the treatment of irritable bowel syndrome. Annaházi A; Róka R; Rosztóczy A; Wittmann T World J Gastroenterol; 2014 May; 20(20):6031-43. PubMed ID: 24876726 [TBL] [Abstract][Full Text] [Related]
8. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. Evangelista S Curr Pharm Des; 2004; 10(28):3561-8. PubMed ID: 15579053 [TBL] [Abstract][Full Text] [Related]
9. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Glende M; Morselli-Labate AM; Battaglia G; Evangelista S Eur J Gastroenterol Hepatol; 2002 Dec; 14(12):1331-8. PubMed ID: 12468954 [TBL] [Abstract][Full Text] [Related]
10. Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Battaglia G; Morselli-Labate AM; Camarri E; Francavilla A; De Marco F; Mastropaolo G; Naccarato R Aliment Pharmacol Ther; 1998 Oct; 12(10):1003-10. PubMed ID: 9798806 [TBL] [Abstract][Full Text] [Related]
11. Effect of herbal extract granules combined with otilonium bromide on irritable bowel syndrome with diarrhoea: a study protocol for a randomised controlled trial. Kim JI; Kim P; Lee JH; Kim YJ; Yang NR; Baeg MK; Choi JS; Kim HJ; Kim J; Sunwoo YY; Lee JH; Ha H; Park TY BMJ Open; 2017 Dec; 7(11):e018362. PubMed ID: 29196484 [TBL] [Abstract][Full Text] [Related]
12. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial. Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995 [TBL] [Abstract][Full Text] [Related]
14. [Efficacy of Kolofort for the treatment of patients with irritable bowel syndrome]. Tsukanov VV; Rzhavicheva OS; Vasjutin AV; Dunaevskaja OV; Tonkih JL; Bronnikova EP Ter Arkh; 2016; 88(8):40-45. PubMed ID: 27636926 [TBL] [Abstract][Full Text] [Related]
15. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents. Thomas RH; Luthin DR Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Rahimi R; Nikfar S; Abdollahi M Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935 [TBL] [Abstract][Full Text] [Related]